Comment from Stephen Kry

Summary: UT MD Anderson Cancer Center supports the proposed pilot program and suggests expanding its scope to include radiopharmaceuticals, which they offer to help pilot. They also recommend that the FDA require centralized radiotherapy quality assurance and standardized nomenclature to ensure the scientific integrity and reliability of AI-enabled analyses in combination trials.